Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,615.73
(
0.47%
)
US TECH 100
29,777.80
(
0.83%
)
Dow Jones
51,030.56
(
0.00%
)
Brent Oil
94.68
(
3.63%
)
Bitcoin
71,528.28
(
-2.76%
)
News Focus
News Focus
Post# of 257670
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123042
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197120

Friday, 03/31/2017 10:53:32 AM

Friday, March 31, 2017 10:53:32 AM

Post# of 257670
CHMP approves Samsung-Bioepis/BIIB’s Enbrel FoB:

http://www.businesswire.com/news/home/20151120005300/en/Samsung-Bioepis-Receives-Positive-CHMP-Opinion-Etanercept

The is the first Enbrel FoB in the EU. BIIB has the marketing rights to this product in the EU, Japan, and Switzerland.

This product will not be commercialized in the US due to AMGN's long-running US Enbrel patent.

Note: The EU does not have a provision for approving interchangeable FoBs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today